February 15, 2018 (Vol. 38, No. 4)

The Binding Site

Several new monoclonal antibodies (mAbs) are now available that focus on infectious diseases including CMV, hepatitis (A, B, C, and D), herpes, HIV, rubella, and Toxoplasma. These products will be of benefit to academic, clinical, biopharmaceutical, and life science researchers, but also in vitro diagnostic manufacturers. All of these mAbs exhibit outstanding degrees of specificity and high levels of purity, extended shelf-life stability claims, and lot-to-lot consistencies. The infectious disease mAbs are all available in a standard-sized 1.0-mg fill format, while the rest come in a standard 0.2-mg fill format. Bulk packaging and customer-specific packaging options are available.

Previous articleSmart Contacts Can Monitor the Glucose in Tears
Next articleNIH Budget Proposal